Response by Omland et al to Letter Regarding Article, “Sacubitril/Valsartan and Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy: The PRADA II Randomized Clinical Trial”

Key Points

• The response clarifies findings regarding the effects of sacubitril/valsartan in preventing cardiac dysfunction associated with breast cancer treatment.
• Discussion of results from the PRADA II randomized clinical trial.
• Focuses on the implications of therapy in the context of adjuvant treatment.
• Sacubitril/valsartan demonstrates potential benefits in reducing cardiac dysfunction risk during breast cancer adjuvant therapy.
• Specific event rates and effect sizes were not detailed in the response.